• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Roche Holding AG ADR

Roche Holding AG ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

    FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

  2. FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

    FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

  3. Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer Without Their Disease Returning Compared to Herceptin® and ...

    Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer Without Their Disease Returning Compared to Herceptin® and Chemotherapy

  4. A Push-Me, Pull-You Market

    Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...

  5. Betting Responsibly on Healthcare

    These funds offer thoughtful investments in healthcare, not tactical plays.

  6. Low-Cost Exposure to U.S. Healthcare Firms

    This ETF holds a swath of large- and mid-cap U.S. healthcare companies.

  7. Roche Builds a Wide Moat With Dominant Oncology and Diagnostics Franchises

    Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.

  8. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.

  9. Ariel Goes Abroad

    Ariel International marks the firm’s first foray into foreign-stock investing. It has been a performance success so far.

  10. Why Retirees Should Consider Investing Abroad

    Readers say diversification and exposure to good companies call for looking beyond the U.S.

1234

©2017 Morningstar Advisor. All right reserved.